Acta Med. 2002, 45: 99-105

Effect of Sodium 2,3-Dimercaptopropane-1-Sulphonate (DMPS) on Chronic Daunorubicin Toxicity in Rabbits: Comparison with Dexrazoxane

Radomír Hrdinaa, Vladimír Geršlb, Ivona Klimtováa, Tomáš Šimůneka, Yvona Mazurovác, Jarmila Macháčkováb, Michaela Adamcovád

aCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology and Toxicology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Histology and Embryology, Hradec Králové, Czech Republic
dCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Physiology, Hradec Králové, Czech Republic

Received April 1, 2002
Accepted May 1, 2002


1. Anonymous. “European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes”. Strasbourg, Council of Europe, 1986.
2. Anonymous. Dexrazoxane for cardiac protection against doxorubicin. Med Lett Drugs Ther 1995; 37:110–1.
3. Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C. Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res 1985; 19:378–82. <>
4. Benov LC, Ribarov SR, Monovich OH. Study of activated oxygen production by some thiols using chemiluminiscence. Gen Physiol Biophys 1992; 11:195–202.
5. Bertolatus JA, Klinzman D, Bronsema DA, Ridnour L, Oberley LW. Evaluation of the role of reactive oxygen species in doxorubicin hydrochloride nephrosis. J Lab Clin Med 1991; 118:435–45.
6. Bocherens-Gadient SA, Quast U, Nussberger J, Brunner HR, Hof RP. Chronic adriamycin treatment and its effect on the cardiac β-adrenergic system in the rabbit. J Cardiovasc Pharmacol 1992; 19:770–8.
7. Cheng WH, Ho YS, Valentine BA, Ross DA, Combs Jr. GF, Lei XG. Cellular glutathione peroxidase is the mediator of body selenium to protect against paraquat lethality in transgenic mice. J Nutr 1998; 128:1070–6. <>
8. Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 222:384–5. <>
9. Dimitrov NV, Hay MB, Siew S, Hudler DA, Charamella LJ, Ullrey DE. Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits. Am J Pathol 1987; 126:376–83.
10. Dioudis C, Grekas D, Papageorgiou G et al. Lipid peroxidation and antioxidant defence mechanisms in rat renal tissue after daunorubicin administration. Ren Fail 1996; 18:537–43. <>
11. Domingo JL. Embryotoxic and teratogenic effects of chelating agents used in the prevention and treatment of metal intoxications. Rev Toxicol 1995; 12:56–64.
12. Geršl V, Cerman J, Šuba P, Mazurová Y, Hrdina R, Macháčková J. IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits. Hum Exp Toxicol 1999; 18:154–61. <>
13. Grankvist K, Stendahl U, Henriksson R. Comparative study of demethoxydaunorubicin with other anthracyclines on generation of oxygen radicals and clonogenic survival of fibroblasts. Pharmacol Toxicol 1989; 65:40–4. <>
14. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5:1–28.
15. Hellmann K. Overview and historical development of dexrazoxane. Semin Oncol 1998; 25(Suppl 10):48–54.
16. Herman EH, Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 1998; 25(Suppl 10):15–21.
17. Herman EH, Ferrans VJ. Pre-treatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 1986; 16:102–6. <>
18. Herman EH, Ferrans VJ. Reduction of chronic doxorubicin cardiotoxicity in dogs by pre-treatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF- 187). Cancer Res 1981; 41:3436–40.
19. Herman EH, Zhang J, Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 1994; 35:93–100. <>
20. Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84:1725–30. <>
21. Jackson JA, Reeves JP, Muntz KH, et al. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 1984; 117: 140–53.
22. Jones MM, Basinger MA. A hypothesis for the selection of chelate antidotes for toxic metals. Med Hypotheses 1982; 9:445–53. <>
23. Jurga L, Mišurová E, Vančík J. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: A preliminary report. Neoplasma 1993; 40:259–62.
24. Kamysbaev DK, Utegulov RN, Ospanov KK. Thermodynamics of the complex formation of metals (II) with unithiol in aqueous solution. Russ J Inorg Chem 1993; 38:288–90.
25. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmac Ther 1990; 47:219–31. <>
26. Lentner C. Heart. Systolic funtion. In: Geigy scientific tables. Heart and circulation. C. Lentner, ed. Basel:Ciba-Geigy Limited, 1990:108.
27. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation on anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996; 127:272–8. <>
28. Lopez M. Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy. Clin Ter 1999; 150:37–49 (abstract).
29. Luo X, Evrovsky Y, Cole D, Trines J, Benson LN, Lehotay DC. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochim Biophys Acta 1997; 1360:45–52.
30. Maiorino RM, Weber GL, Aposhian HV. Determination and metabolism of dithiol chelating agents. III. Formation of oxidized metabolites of 2,3-dimercaptopropane-1-sulfonic acid in rabbits. Drug Metab Dispos 1994; 16:455–63.
31. Mansour MA, El-Kashef HA, Al-Shabanah OA. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol Res 1999; 39:233–7. <>
32. Milner LS, Wei SH, Houser MT. Amelioration of glomerular injury in doxorubicin hydrochloride nephrosis by dimethylthiourea. J Lab Clin Med 1991; 118: 427–34.
33. Miwa N, Kanaide H, Meno H, Nakamura M. Adriamycin and altered membrane functions in rat hearts. Br J Exp Path 1986; 67:747–55.
34. Seifert CF, Thompson DF, Nesser ME. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994; 28:1063–72. <>
35. Stewart JR, Diamond GL. In vivo renal tubular secretion and metabolism of the disulfide of 2,3-dimercaptopropane-1-sulfonate. Drug Metab Dispos 1988; 16: 189–95.
36. Szinicz L, Wiedemann P, Häring H, Weger N. Effects of repeated treatment with sodium 2,3-dimercaptopropane-1-sulfonate in beagle dogs. Arzneim Forsch/Drug Res 1983; 33:818–21.
37. Takahashi S, Denvir MA, Harder L, et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in “chemically-skinned” rabbit trabeculae. Jpn J Pharmacol 1998; 76:405–13. <>
38. Takahashi Y, Funakoshi T, Shimada H, Kojima S. The utility of chelating agents as antidotes for nephrotoxicity of gold sodium thiomalate in adjuvant-arthritic rats. Toxicology 1995; 97:151–7. <>
39. van Acker SA, Boven E, Kuiper K, et al. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect antitumour activity of doxorubicin. Clin Cancer Res 1997; 3:1747–54.
40. van Acker SABE, Voest EE, Beems DB, et al. Cardioprotective properties of O-(β-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Res 1993; 53:4603–7.
41. van Vleet JF, Ferrans VJ. Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits. Cancer Treat Rep 1980; 64:315–7.
42. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000; 129:231–4. <> <PubMed>
43. von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710–7. <>
44. Weiss G, Loyevsky M, Gordeuk VR. Dexrazoxane (ICRF-187). Gen Pharmacol 1999; 32:155–8. <>
45. Wexler LH, Andrich MP, Venzon D et al. Randomized trial of the cardioprotective agent ICFR-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14:362–72. <>
46. Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001; 68:889–901. <>
47. Yin X, Wu H, Chen Y, Kang YJ. Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol 1998; 56:87–93. <>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal